Royalty finance comes of age

In a rebounding biotech market, royalty finance can play a far more strategic role, provided it’s executed with disciplined underwriting, smart structuring and a genuine partnership with innovators, according to Ryan Murr a partner at Gibson, Dunn & Crutcher.